Shares of Hikma Pharmaceuticals Plc (LON:HIK) have earned an average rating of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is GBX 1,775 ($23.19).
HIK has been the topic of several recent research reports. Barclays reissued an “underweight” rating on shares of Hikma Pharmaceuticals in a report on Tuesday, October 9th. Peel Hunt reissued an “add” rating on shares of Hikma Pharmaceuticals in a report on Tuesday, October 23rd. Citigroup reissued a “buy” rating and issued a GBX 2,250 ($29.40) price target on shares of Hikma Pharmaceuticals in a report on Tuesday, October 30th. JPMorgan Chase & Co. raised their target price on Hikma Pharmaceuticals from GBX 1,050 ($13.72) to GBX 1,900 ($24.83) and gave the company a “neutral” rating in a research report on Tuesday, November 20th. Finally, Jefferies Financial Group upgraded Hikma Pharmaceuticals to a “buy” rating and raised their target price for the company from GBX 1,643 ($21.47) to GBX 2,000 ($26.13) in a research report on Tuesday, November 27th.
Shares of LON HIK traded up GBX 26.50 ($0.35) during mid-day trading on Tuesday, hitting GBX 1,661.50 ($21.71). The company had a trading volume of 255,733 shares, compared to its average volume of 822,138. Hikma Pharmaceuticals has a 12 month low of GBX 814.20 ($10.64) and a 12 month high of GBX 2,346 ($30.65).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
See Also: Back-End Load
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.